BPC-157

BPC-157 is a pentadecapeptide, a 15-amino-acid stretch of a larger "body protection compound" first isolated from human gastric juice [1]. Its sequence is GEPPPGKPADDAGLV [5]. A 2006 review lists the development codes PL 10, PLD 116 and PL 14736 and describes it as safe in trials for inflammatory bowel disease, but gives no trial data [6].

Animal evidence. A 2025 systematic review from an orthopedic sports medicine perspective found 36 studies: 35 preclinical and one clinical. In animals, BPC-157 improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injuries [2]. An earlier review noted that every study had been positive, but that most used small rodents and came from only a handful of research groups [3]. That review also notes that rodent work has delivered the peptide by three routes with positive results - intraperitoneal injection, drinking water and a topical cream - including a 90-day ligament study that compared all three [3].

Human evidence. Three pilot reports exist. All share a first author and were done in private clinics [7][8][9]:

• A retrospective phone survey of 16 people who had had knee injections: 11 of 12 given BPC-157 alone reported significant pain relief. No standard measures of pain or function were used [7].
• Twelve women with interstitial cystitis who had not responded to pentosan polysulfate had BPC-157 injected into the bladder wall. Ten reported complete resolution of symptoms. There was no control group [8].
• Two adults received intravenous infusions of 10 mg and 20 mg on consecutive days, with no changes in heart, liver, kidney, thyroid or glucose markers [9].

It is not approved by the US FDA and is banned in professional sport, yet clinicians and athletes increasingly use it [2].

Angiogenesis. BPC-157 raised vessel density in the chick chorioallantoic membrane assay and in an endothelial tube-formation assay, and in rats whose hind-limb artery had been blocked it sped the return of blood flow measured by laser Doppler, with more vessels and more vascular VEGFR2 on histology. In human vascular endothelial cells it raised VEGFR2 mRNA and protein but left VEGF-A unchanged, so it appears to make cells more responsive to the growth factor rather than to supply more of it. It also drove VEGFR2 internalization and, over time, activation of the VEGFR2-Akt-eNOS pathway. Dynasore, which blocks endocytosis, abolished the internalization, the signaling and the extra tube formation - the control that ties the angiogenic effect to receptor trafficking rather than to binding at the cell surface [10].

Tendon fibroblasts. In explants of rat Achilles tendon, BPC-157 accelerated the outgrowth of fibroblasts. It did not make the cells divide faster in an MTT assay, but it increased their survival under hydrogen peroxide stress, and increased their migration in a transwell assay and their spreading on culture dishes, both dose-dependently, with visible F-actin assembly. Phosphorylation of FAK and paxillin rose with dose while the total amount of each protein did not, which is what the authors take as the mechanism of the migration effect [1].

Growth hormone receptor. A cDNA microarray of treated rat tendon fibroblasts put the growth hormone receptor among the most up-regulated genes, at 2.3-fold. At 0.1-0.5 µg/mL, receptor mRNA and protein then rose with both dose and time, reaching roughly sevenfold by day three. Adding growth hormone to pre-treated cells increased the number of viable cells and PCNA expression, and phosphorylated JAK2 - the kinase immediately downstream of the receptor - rose while total JAK2 did not. Because BPC-157 on its own does not make these cells proliferate, the reading is that it sensitizes tendon fibroblasts to growth hormone rather than acting as a mitogen itself [11].

Reviews add nitric oxide signaling, ERK1/2 and reduced inflammatory cytokines to this list [2][4]. All of it is cell culture and rodent work; no mechanistic study has been done in people.

There are no clinical safety data beyond the pilot reports. Preclinical safety studies found no adverse effects across several organ systems [2]. The three human reports recorded no adverse events, but they involved 2 to 16 people, with no control groups and short or informal follow-up [7][8][9].

What the record shows, rather than what is missing: the 35 preclinical studies collected in the 2025 review span muscle, tendon, ligament and bone injury and reported no adverse effects across several organ systems [2], the peptide is cleared within about half an hour in rats and dogs and broken down to ordinary amino acids [12], and the two people given 10 mg and then 20 mg intravenously showed no change in cardiac, liver, kidney, thyroid or glucose markers [9]. That is a reassuring picture, but a thin one: it is not a trial designed to find uncommon harms. Anti-doping labs have a urine test for it [5].